There has been a great deal of controversy in recent years regarding the efficacy of antidepressants in acute depression. As a result of some of that public debate, the FDA conducted an internal review of a related but different question: the long-term maintenance efficacy of antidepressants.
The issue of long-term efficacy has been discussed in research circles for some years in relation to a question of methodological bias. The FDA review sought to address some of those concerns.
In this summary, PL will examine the debate, and what the FDA concluded, and what PL thinks.